Mueller - Die lila Logistik SE MLL

Suominen Corporation's stock exchange release on October 1, 2026, at 3:15 p.m. (EEST) Suominen Corporation (hereinafter the “Company”) has transferred without consideration a total of 324,000 of Company shares held by the Company as treasury shares to President and CEO Charles Héaulmé as a signing bonus on September 30, 2026. As previously announced in the Company’s financial statements release on January 29, 2026, and the interim reports published on May 7, 2026, and on August 7, 2026, the Pres

Investing.com -- Deutsche Bank on Thursday named its top European stock picks for the next 12 months, adding six new names and dropping six from its third-quarter list.

Suominen Corporation October 1, 2026, at 3:00 p.m. (EEST) Suominen Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Charles Héaulmé Position: Chief Executive Officer Issuer: Suominen Oyj LEI: 743700Z1BNFYR9PRDF52 Notification type: INITIAL NOTIFICATION Reference number: 174870/6/6 ____________________________________________ Transaction date: 2026-09-30 Outside a trading venue Instrument type: SHARE ISIN: FI0009010862

Dama Solar is scheduled to enter commercial operations in H2 2028.

Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company's next phase of growth.

AI-driven discovery, streamlined approvals and partnerships are accelerating drug repurposing, creating opportunities in oncology, rare, neurodegenerative and infectious diseases.Dublin, Sept. 30, 2026 (GLOBE NEWSWIRE) -- "Drug Repurposing Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global drug repurposing market was valued at US$29.4 billion in 2024 and is projected to reach US$37.3 billion by 2030, expanding at a compound annual growth ra

The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026

SCHRAMBERG, GERMANY - September 29, 2026 (NEWMEDIAWIRE) - Shares in Schweizer Electronic AG (ISIN: DE0005156236, WKN: 515623) will be traded on the Scale segment of the Frankfurt Stock Exchange from 30 September 2026. The company is thus completin...

CAS, a division of the American Chemical Society, today announced a collaboration with Novartis Biomedical Research focused on enhancing reaction data accessibility and supporting AI-enabled research. The initiative will leverage CAS unique scientific data curation expertise and science-smart technology to give Novartis researchers integrated, searchable access to proprietary experimental reaction data alongside more than 160 million+ scientist-curated reactions from the authoritative CAS Conten

Estonia’s Finance Minister Jurgen Ligi characterised the bank’s Russian footprint as a “moral disgrace.”

Investing.com -- Global chip stocks rose on Tuesday after Reuters reported that AI startup Anthropic’s IPO prospectus showed it expects $518 billion in cloud, computing and infrastructure commitments over the coming year.

Investing.com - European stock bourses reversed course on Tuesday, closing lower, as investors continued to digest a spike in global bond yields and oil volatility.

Arthex Biotech, a clinical-stage biotechnology company advancing RNA-based therapeutics for neuromuscular disorders, today announced the appointment of Glenn Sblendorio, M.B.A., as Chairman of its Board of Directors. Mr. Sblendorio is a seasoned biotechnology executive and board member with more than three decades of experience leading corporate strategy, finance, business development and capital markets initiatives. Most recently, he was Chief Executive Officer of IVERIC bio, Inc. (acquired by

Today, NKT hosts Investor Day 2026 in Karlskrona, Sweden, providing additional insights into the execution of its Charging Forward strategy and presents capital allocation priorities to support long-term value creation.

On September 18, Novartis AG (NYSE:NVS) announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization for Cosentyx (secukinumab) to treat polymyalgia rheumatica (PMR) in adults who respond inadequately to steroids or relapse during tapering. Following this recommendation, the European Commission is expected to issue a […]

Klépierre (ENXTPA:LI) drew investor attention after its share price closed at €36.52, with recent returns mixed over the past month and the past 3 months for the European shopping mall specialist. Recent moves paint a mixed picture for Klépierre, with the share price up 9.67% year to date but down 3.28% over the past month. At the same time, a 1-year total shareholder return of 16.72% and 3-year total shareholder return of 91.49% suggest that longer term momentum has been stronger than the...

Space-based communications just had a spotlight moment as SpaceX’s Starship carried a fresh batch of Starlink satellites into orbit, and that test has many investors rethinking what satellite internet exposure really means. This surge in attention can create openings where prices move faster than understanding. This article unpacks that story and profiles 3 stocks tied to the same news pulse so you can judge the risk and potential reward for yourself. The stocks highlighted below are only a...

Gecina (ENXTPA:GFC) has drawn investor attention after recent trading left the stock flat on the day but down over the past month and the past 3 months, prompting closer scrutiny of its €4.7b valuation. That weaker short term momentum, with a 7 day share price return down 2.7% and a 30 day move down 8.9%, sits on top of a longer slide that leaves Gecina with a year to date share price decline of 20.5% and a 1 year total shareholder return down 17.6%. This suggests that recent sellers are...

On September 1, 2026, the Wall Street Journal first reported that Novartis AG (NYSE:NVS) paused eight clinical trials of its experimental CAR-T cell therapy rap-cel in autoimmune and neurological conditions, including lupus, rheumatoid arthritis, and multiple sclerosis. It happened after three patients died from immune effector cell-associated hemophagocytic syndrome, a rare and severe immune reaction. […]

Big pharma is still paying up, but more often for delivery and discovery engines than for a single late-stage asset.